Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
A report in The Daily Telegraph today states that “experts at King’s College London have now found the proportion of men with prostate cancer who actually die from it to be higher than previously thought.” Supposedly, the new research finding is that for 49 percent of 20,000 men diagnosed between 1997 and 2007 “prostate cancer [...]
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: mortality, prostate cancer-specific, UK, United Kingdom | 7 Comments »
The Prostate Research, Outreach, Screening, Testing, Access and Treatment Effectiveness (PROSTATE) Act of 2011 (H.R. 2159), was re-introduced yesterday in the U.S. House of Representatives and companion legislation (S. 1190) was re-introduced in the U.S. Senate.
Filed under: Uncategorized | Leave a Comment »
Let us be clear up front … Duloxetine (Cymbalta®) has not been approved anywhere in the world that we are aware of as a treatment for post-surgical incontinence in men treated for prostate cancer, and there has never been a large, randomized, double-blind Phase III trial to try to demonstrate such activity.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: duloxetine, incontinence, stress, surgery | Leave a Comment »
A new paper in the European Journal of Cancer suggests that men with prostate cancer are at increased risk for depression, for post-traumatic stress disorder, and for use of antidepressant drugs compared to age-matched controls.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: anxiety, depression, post-traumatic stress disorder, risk, Sweden, Treatment | 3 Comments »
Some readers will be interested in the article by Thomas Gyrta published today in The Wall Street Journal. While this article is not specific to prostate cancer, the potential to apply immunotherapy in treatment of prostate cancer is at least well appreciated.
Filed under: Uncategorized | Tagged: immunotherapy | 1 Comment »
A large study in the United Kingdom — the PROMIS study — will shortly start to recruit patients in an attempt to see whether multi-parametric magnetic resonance imaging (MP-MRI) can help find prostate cancer and learn the extent of disease prior to prostate biopsy.
Filed under: Diagnosis, Risk | Tagged: biopsy, Diagnosis, magnetic resonance imaging, MRI | 1 Comment »
An updated, systematic review just published in Annals of Internal Medicine states that it is impossible to come to any conclusions about the efficacy of radiation therapy compared with active surveillance or watchful waiting for the management of localized prostate cancer because of the absence of any high-quality, comparative data.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: benefit, comparative, localized, outcome, radiation | Leave a Comment »
A recent study published in “The Red Journal” suggests (perhaps not surprisingly) that radiation oncologists and urologists have different mindsets about the application of immediate adjuvant radiation therapy following surgery for prostate cancer patients with a variety of adverse pathologic risk factors.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: adjuvant, radiation, salvage, second-line | 7 Comments »
An article in the April issue of Clinical Medical Insights: Oncology suggests that a rapid post-treatment increase in the PSA levels of men treated for localized prostate cancer with high-intensity focused ultrasound (HIFU) may indicate later risk for biochemical recurrence.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: HIFU, high-intensity focused ultrasound, progression, PSA, rapid, rise, risk | 3 Comments »
The full text of a “consensus” review entitled “The contemporary concept of significant versus insignificant prostate cancer” has just been published on line in European Urology. The authors include opinion-leaders from the USA, France, Italy, Germany, Sweden and Canada.
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: active surveillance, biologically, clinically, insignificant, significant | Leave a Comment »
OK all you US citizens … Time to exercise your civil rights! … Let’s give this one more shot … Please contact The White House and ask for it to be lit up in blue one night during Prostate Cancer Awareness month this September!
Filed under: Uncategorized | 1 Comment »
Yesterday the US Food & Drug Administration (FDA) updated its guidance on the use of 5α-reductase inhibitors with specific reference to the risk that use of these products may be able to induce high-grade (and therefore high-risk) prostate cancer in a small subset of men treated with these agents.
Filed under: Diagnosis, Prevention, Risk | Tagged: 5-ARI, dutasteride, FDA, finasteride, Prevention, risk | 4 Comments »
Some readers of The “New” Prostate Cancer InfoLink will be interested in a new article with the above title by Prof. Emil Freireich, MD, that appears in the most recent issue of The ASCO Post. Professor Freireich’s opinion is certainly stimulating, although the problem as described and the solution as proposed may not be quite [...]
Filed under: Drugs in development | Tagged: drug development, FDA | Leave a Comment »
A new study has suggested that a clinical algorithm that combines data on serum PSA with detection of TMPRSS2:ERG fusion and prostate cancer gene 3 (PCA3) in urine collected after a digital rectal exam (DRE) can predict prostate cancer on subsequent biopsy better than any one of the three potential markers alone.
Filed under: Diagnosis, Risk | Tagged: algorithm, biopsy, PCA3, PSA, risk, TMPRSS2:ERG | Leave a Comment »
With the failure of Combidex (ferumoxtran-10) to achieve FDA approval as an imaging agent for lymph node-positive prostate cancer and the recognized limitations of the ProstaScint (capromab pendetide) scan, there is a widely acknowledged need for a much more specific and accurate prostate cancer imaging agent than anything currently available.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Endocyte, imaging, prostate cancer-specific, Purdue | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site